ALM 001
Alternative Names: ALM-001Latest Information Update: 18 Jul 2022
At a glance
- Originator Almatica Pharma
- Class Neuropsychotherapeutics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Mental disorders
Most Recent Events
- 11 Jul 2022 Almatica Pharma intends to files an IND application (Almatica Pharma pipeline, July 2022)
- 11 Jul 2022 Phase-III trial for Mental disorders in USA (unspecified route) (Almatica Pharma pipeline; July 2022)